TAMPA, FL — In a move that has sent shockwaves through the advocacy community and the corporate healthcare sector, the Obesity Action Coalition (OAC) has issued a formal call to action against PepsiCo. The coalition is demanding that the global food and beverage giant reverse its recently reported decision to terminate insurance coverage for GLP-1 (glucagon-like peptide-1) medications used for obesity treatment for a significant portion of its workforce.
n
The decision, slated to take effect in October 2026, highlights a growing tension in American corporate culture: the balance between managing skyrocketing pharmacy benefit costs and the ethical obligation to treat obesity as a chronic, biological disease rather than a lifestyle choice.
n
Main Facts: The Conflict Between Coverage and Cost
n
The Obesity Action Coalition, the nation’s leading nonprofit organization representing individuals affected by obesity, expressed "deep concern" following reports that PepsiCo would be scaling back its healthcare benefits. According to the OAC, PepsiCo plans to end coverage for GLP-1 medications—a class of drugs including semaglutide and tirzepatide that have revolutionized weight management—for certain employee groups.
n
PepsiCo has reportedly justified the move as a necessary measure to ensure the "sustainability and affordability" of its broader healthcare plan. However, the OAC argues that this strategy is fundamentally flawed. By excluding a specific class of treatment for a specific disease, the coalition contends that PepsiCo is failing to provide healthcare for all employees, effectively marginalizing those with obesity.
n
Central to the dispute is the proposed alternative for employees: manufacturer self-pay programs. While these programs can reduce the out-of-pocket cost of medications, the OAC points out that they still require employees to pay between $300 and $500 per month. For many workers, this represents an insurmountable financial barrier, rendering the treatment effectively inaccessible despite its technical availability on the market.
n
Chronology: The Rise of GLP-1s and the Corporate Retreat
n
To understand the weight of this decision, one must look at the timeline of GLP-1 medications and their integration into corporate America.
n
- n
- 2021–2023: The Breakthrough Era. The FDA approval of medications like Wegovy and later Zepbound transformed the landscape of obesity treatment. Unlike previous generations of weight-loss drugs, GLP-1s showed clinical efficacy comparable to bariatric surgery. Demand exploded, and many forward-thinking Fortune 500 companies, including PepsiCo, initially added these drugs to their formularies to support employee wellness.
- 2024–2025: The Financial Strain. As adoption rates soared, so did the costs for employers. By mid-2025, many large corporations reported that weight-loss medications had become one of their top three pharmacy expenses, sometimes rivaling specialty oncology drugs.
- Early 2026: The Policy Shift. Throughout the first half of 2026, several large employers began implementing "utilization management" strategies, such as requiring rigorous prior authorizations or mandatory participation in lifestyle coaching.
- September 2, 2026: The OAC Call to Action. The OAC officially goes public with its challenge to PepsiCo, identifying the October 1st deadline as a critical turning point for thousands of employees who may be forced to discontinue life-changing treatment mid-course.
n
n
n
n
n
Supporting Data: The Economics of Obesity and Treatment
n
The debate over GLP-1 coverage is underpinned by staggering statistics regarding both the cost of the medications and the cost of the disease they treat.
n
The Cost of the Disease
n
Obesity is not merely a cosmetic concern; it is a primary driver of dozens of comorbid conditions, including Type 2 diabetes, hypertension, sleep apnea, and various cancers. Data from the Centers for Disease Control and Prevention (CDC) suggests that the medical costs of obesity in the United States are nearly $173 billion annually. Employees with obesity have historically higher rates of absenteeism and "presenteeism" (lower productivity while at work), costing employers billions in lost output.
n
The Cost of the Cure
n
GLP-1 medications carry high list prices, often exceeding $1,000 per month. While pharmacy benefit managers (PBMs) negotiate rebates, the net cost to the employer remains significant. However, proponents of coverage argue that these costs should be viewed as a long-term investment. A 2025 study published in The Journal of Managed Care & Specialty Pharmacy suggested that for every dollar spent on effective obesity treatment, employers could see a return on investment through reduced costs for treating related chronic conditions within three to five years.
n
The Self-Pay Fallacy
n
The OAC’s critique of the $300–$500 self-pay model is backed by economic reality. According to the Federal Reserve, a significant percentage of American households struggle to cover an unexpected $400 emergency expense. Expecting an employee to pay that amount every month for a maintenance medication is, in the eyes of the OAC, a "de facto denial of care."
n
Official Responses: Advocacy vs. Corporate Strategy
n
The OAC’s leadership has been vocal about the precedent this sets for the labor market.
n
“If PepsiCo is committed to protecting healthcare for all employees, that must include employees living with obesity,” said Joe Nadglowski, OAC President and CEO. “Obesity is a chronic disease, and its treatment should not be singled out for exclusion. Health plans routinely cover medications at a range of costs. Obesity treatment deserves the same consideration.”
n
The OAC’s Marketing and Communications Manager, Gianna Toto, emphasized that the coalition is not just issuing a statement but is mobilizing a national campaign. The OAC has launched an action center, encouraging the public and PepsiCo employees to contact the company’s leadership to voice their opposition.
n
PepsiCo’s PositionnWhile PepsiCo has not issued a new public manifesto in response to the OAC’s September 2nd statement, their internal communications to employees—leaked earlier this summer—frame the decision as a matter of fiscal responsibility. The company maintains that the rising costs of these specific medications threaten the stability of the entire benefits package, potentially leading to higher premiums for all staff if not curtailed.
n
However, the OAC finds this "sustainability" argument difficult to reconcile with PepsiCo’s recent business maneuvers.
n
Implications: The Irony of the "GLP-1 Economy"
Perhaps the most stinging part of the OAC’s critique is the highlight of PepsiCo’s dual-track strategy. While the company is cutting coverage for the drugs for its workers, it is simultaneously pivoting its product development to profit from the "GLP-1 consumer."
The "Propel Clear Protein" Paradox
PepsiCo CEO Ramon Laguarta has publicly discussed the company’s evolution to meet the needs of people on weight-loss medications. These patients often require higher protein intake and increased hydration. In response, PepsiCo has fast-tracked products like Propel Clear Protein.
“PepsiCo should not view people using GLP-1s as consumers worth investing in while making treatment harder to access for its own employees,” the OAC stated. This perceived hypocrisy—marketing to a demographic while denying the same medical support to their own staff—could pose a significant brand reputation risk for a company that prides itself on "Winning with Purpose."
A Precedent for the Fortune 500
The outcome of this standoff will likely serve as a bellwether for other major employers. If a giant like PepsiCo successfully rolls back coverage without significant blowback, other companies may follow suit, potentially reverting obesity care to the "pre-GLP-1" era where patients were largely left to fend for themselves.
Conversely, if the OAC’s advocacy leads to a reversal or a compromise (such as tiered coverage or more robust subsidies), it could solidify the status of obesity medications as a standard, non-negotiable component of a modern benefits package.
The Legal and Ethical Horizon
Legal experts suggest that as obesity is increasingly recognized as a disability under the Americans with Disabilities Act (ADA) in various jurisdictions, the selective removal of coverage for obesity treatments could eventually face challenges in court. By "singling out" obesity for exclusion while continuing to cover treatments for other chronic conditions like heart disease or asthma, companies may be opening themselves up to claims of discrimination.
Conclusion: A Call for Equitable Access
The OAC’s campaign against PepsiCo is more than a dispute over a single insurance line item; it is a battle for the soul of corporate healthcare. As the October deadline approaches, the eyes of the healthcare industry, the food and beverage sector, and millions of patients are on Purchase, New York.
The OAC remains steadfast: "Tell PepsiCo that employees living with obesity deserve equitable access to treatment and that cutting coverage for obesity care is not consistent with a commitment to providing healthcare for all employees."
For now, the OAC continues to urge individuals across the country to take action through their online portal, hoping that public pressure will convince the beverage giant that the health of its workforce is a cost worth carrying.
About the Obesity Action Coalition (OAC):
The OAC is a national nonprofit organization dedicated to improving the lives of individuals affected by obesity through education, advocacy, and support. As the nation’s leading voice for those impacted by obesity, the OAC works to eliminate weight bias and ensure that obesity is treated with the same urgency and respect as any other chronic disease. For more information, visit www.obesityaction.org.
